Head-To-Head Analysis: Aquinox Pharmaceuticals (AQXP) versus Its Rivals
Aquinox Pharmaceuticals (NASDAQ: AQXP) is one of 112 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Aquinox Pharmaceuticals to related businesses based on the strength of its earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.
This table compares Aquinox Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aquinox Pharmaceuticals Competitors||-3,612.23%||-53.37%||-8.67%|
Risk & Volatility
Aquinox Pharmaceuticals has a beta of -16.98, suggesting that its stock price is 1,798% less volatile than the S&P 500. Comparatively, Aquinox Pharmaceuticals’ rivals have a beta of 0.86, suggesting that their average stock price is 14% less volatile than the S&P 500.
Valuation & Earnings
This table compares Aquinox Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Aquinox Pharmaceuticals Competitors||$7.78 billion||$2.46 billion||1.04|
Aquinox Pharmaceuticals’ rivals have higher revenue and earnings than Aquinox Pharmaceuticals. Aquinox Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
95.2% of Aquinox Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.7% of Aquinox Pharmaceuticals shares are owned by insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Aquinox Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aquinox Pharmaceuticals Competitors||944||3794||6014||164||2.49|
Aquinox Pharmaceuticals presently has a consensus target price of $24.67, indicating a potential upside of 79.39%. As a group, “Pharmaceuticals” companies have a potential upside of 25.59%. Given Aquinox Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Aquinox Pharmaceuticals is more favorable than its rivals.
Aquinox Pharmaceuticals beats its rivals on 6 of the 11 factors compared.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.